Malaysia Company Guide

British American Tobacco

Version 17 | Bloomberg: ROTH MK | Reuters: BATO.KL

Refer to important disclosures at the end of this report

DBS Group Research . Equity

BUY

Last Traded Price (24 Mar 2020): RM9.61 (KLCI: 1,291.14)
Price Target 12-mth: RM11.90 (24% upside) (Prev RM17.10)
Analyst

Abdul Azim Muhthar +60 32604 3967 azimm@alliancedbs.com

What's New

- COVID-19 pandemic to impact sales volume, weak consumer sentiment may lead to further down trading
- Cut FY20/21F earnings forecast by 17%/10% on lower ASP assumptions
- Trading at 10x forward EPS, or -3 SD of its 10-year mean; attractive dividend yield
- Maintain BUY with lower TP of RM11.90

Price Relative RM Relative Index 58.3 48.3 48.3 28.3 28.3 8.3 Mar-16 Mar-17 Mar-18 Mar-19 Mar-20

| Forecasts and Valuation | | | | |
|--------------------------|--------|--------|-------|-------|
| FY Dec (RMm) | 2019A | 2020F | 2021F | 2022F |
| Revenue | 2,509 | 2,439 | 2,488 | 2,500 |
| EBITDA | 514 | 392 | 429 | 437 |
| Pre-tax Profit | 464 | 359 | 393 | 398 |
| Net Profit | 346 | 268 | 294 | 298 |
| Net Pft (Pre Ex.) | 367 | 268 | 294 | 298 |
| Net Pft Gth (Pre-ex) (%) | (18.2) | (26.8) | 9.4 | 1.3 |
| EPS (sen) | 121 | 94.0 | 103 | 104 |
| EPS Pre Ex. (sen) | 129 | 94.0 | 103 | 104 |
| EPS Gth Pre Ex (%) | (18) | (27) | 9 | 1 |
| Diluted EPS (sen) | 129 | 94.0 | 103 | 104 |
| Net DPS (sen) | 118 | 84.6 | 92.6 | 93.8 |
| BV Per Share (sen) | 136 | 134 | 146 | 157 |
| PE (X) | 7.9 | 10.2 | 9.3 | 9.2 |
| PE Pre Ex. (X) | 7.5 | 10.2 | 9.3 | 9.2 |
| P/Cash Flow (X) | 8.3 | 8.7 | 8.5 | 8.2 |
| EV/EBITDA (X) | 6.1 | 8.0 | 7.3 | 7.1 |
| Net Div Yield (%) | 12.3 | 8.8 | 9.6 | 9.8 |
| P/Book Value (X) | 7.1 | 7.2 | 6.6 | 6.1 |
| Net Debt/Equity (X) | 1.0 | 1.1 | 0.9 | 0.8 |
| ROAE (%) | 85.3 | 69.7 | 73.6 | 68.9 |
| Earnings Rev (%): | | (17) | (10) | N/A |
| Consensus EPS (sen): | | 116 | 118 | N/A |
| Other Broker Recs: | | B: 6 | S: 5 | H: 6 |

Source of all data on this page: Company, AllianceDBS, Bloomberg Finance L.P

25 Mar 2020

Value emerging

Attractive valuation; maintain BUY. We expect the ongoing COVID-19 outbreak to lead to lower sales volume and impact British American Tobacco's (ROTH) earnings. Coupled with weak consumer sentiment and slowdown in the economy, these may lead to further down trading by consumers. As such, we cut our FY20/21F earnings forecast by 17%/10%. However, we believe this has been more than priced in with ROTH's 24% m-o-m share price drop. Its valuation is now attractive given that the stock is currently trading at 10x FY20F EPS or -3 SD of its 10-year mean. At current price, the stock offers attractive dividend yield of c.9%.

Where we differ: More conservative than consensus. We assume lower ASP due to down trading. A prolonged outbreak could see further downside to our earnings assumptions. ROTH is expected to be more prudent in spending if consumer sentiment continues to weaken. This could be done by managing its marketing costs and postponing some planned expenditure. These were part of ROTH's initiatives in FY19. Excluding its restructuring exercise and inventory write down, its operating expenses fell by 18% y-o-y in FY19.

Potential catalysts: Faster recovery from COVID-19. A faster recovery from the COVID-19 outbreak would minimise the impact on ROTH's sales volume and reduce spillover effects to the overall economy. The market share for illegal cigarettes has dropped from 74% in 3Q19 to 68% in 4Q19. Further declines would provide a positive boost to ROTH's earnings and share price.

Valuation:

Post-earnings revision, we lower our DCF-based TP (WACC: 8.2%; TG: 0.5%) to RM11.90 – implying 13x FY20 PE.

Kev Risks to Our View:

A prolonged COVID-19 outbreak would further drag sales volume.

At A Glance

| Issued Capital (m shrs) | 286 |
|-----------------------------|-------------|
| Mkt. Cap (RMm/US\$m) | 2,744 / 618 |
| Major Shareholders (%) | |
| British American Tobacco BV | 50.0 |
| Aberdeen Asset | 5.0 |
| Employees Provident Fund | 3.8 |
| Free Float (%) | 42.3 |
| 3m Avg. Daily Val (US\$m) | 5.6 |

GIC Industry: Consumer Staples / Food, Beverage & Tobacco



ed: KK/ sa: WMT. PY. CS





WHAT'S NEW

Possible increase in down trading priced in

Economic slowdown could result in down trading. A prolonged COVID-19 outbreak is likely to have spillover effects on the economy and affect consumer spending. For tobacco players, this could result in down trading. In such a scenario, we believe ROTH's Rothman cigarettes would be least affected, followed by Dunhill and Peter Stuyvesant. Rothman is the company's cheapest brand and has gained market share since it was reintroduced to the local market back in 4QFY17. Now, it controls 32% market share in the

Value-for-Money (VFM) segment and 6.7% in overall legal

Rothman gaining strength

market share.



Source: Company

Dunhill's market share has stabilised despite; 1) a price hike in November 2018 (by RM0.40/pack) and, 2) increasing competition from VFM and illegal cigarettes. We believe that demand for Dunhill should be more resilient compared to Peter Stuyvesant. Now, it commands 60% market share in the premium segment and 35.5% in the overall legal market share.

Dunhill's market share steady even after SST new pricing



Source: Company


The biggest loser for ROTH is its Peter Stuyvesant brand in the aspirational premium segment, in our view. Most consumers in this segment have down traded to VFM or switched to illegal cigarettes. This was one of the main reasons for the reintroduction of the Rothman brand.

Lower illegal cigarettes' market share would be key earnings driver. The market share for illegal cigarettes has dropped from 74% in 3Q19 to 68% in 4Q19, as a result of continuous efforts by local authorities to clamp down on illegal trades. While we have assumed the market share for illegal cigarettes remains at 68% in the near term given weak consumer sentiment, a drop in share of illicit cigarettes from stricter enforcement would be a key catalyst for the stock. The COVID-19 outbreak could disrupt the supply chain for illegal cigarettes with tightening border controls – which might reduce illegal market share as well. Further declines would provide a positive boost to ROTH's earnings and share price.

Increase in excise duty unlikely. The market share for illegal cigarettes has strong correlation with cigarette prices – an increase in cigarette prices (predominantly due to higher excise and sales tax) is likely to lead to an increase in consumption of illicit cigarettes.

Despite expectation of lower gross domestic product (GDP) and the recent oil price crash affecting the government's coffers, we do not expect an increase in excise duty to compensate for these shortfalls. This is because the tobacco industry is still struggling with high illegal trades. Another tax hike could make it even worse for the industry and consumers.

4Q19 saw positive retreat in illegal market share




Source: Company



Better cost control is more important than ever. ROTH is expected to be more prudent in spending if consumer sentiment continues to weaken. This could be done by managing its marketing costs and postponing some planned expenditure. These were part of ROTH's initiatives in FY19. To recap, excluding its restructuring exercise and inventory write down, its operating expenses in FY19 fell by 18% y-o-y (FY18: -4% y-o-y).


Cut FY20-21F earnings forecast by 17%/10%. We cut our FY20-21F earnings forecast by 17% and 10% as we lower our sales volume (to 0% from 4%) and average ASP assumptions (due to down trading) from 70sen/stick to 68sen/stick.

ASP has fallen from peak in 4Q18; more potential downside on down trading



*Changes in ASP largely due to change in sales mix Source: Company, AllianceDBS Maintain BUY with revised TP of RM11.90. ROTH's share price fell 24% m-o-m and is now at the lowest levels since 1989. Its valuation is attractive given that the stock is currently trading at 10x FY20F EPS or -3 SD of its 10-year mean. At current price, the stock offers attractive dividend yield of c.9% (assuming 90% payout). Post-earnings revision, we lower our TP to RM11.90 – implying PE of 13x FY20.

Value emerging: Trading close to -3 SD of 10-year mean (PE)



Source: AllianceDBS, Bloomberg Finance L.P

Sensitivity of FY20 earnings to sales volume and ASP

| Sales Volume Growth (row) EBIT ASP/stick (column) | 0% | -5% | -10% | -15% | -20% | -25% |
|--|-------|-------|-------|-------|-------|-------|
| 70.0 | 312.4 | 296.3 | 280.2 | 264.1 | 248.0 | 231.8 |
| 69.0 | 289.8 | 274.8 | 259.8 | 244.8 | 229.8 | 214.8 |
| 68.0 | 268.3 | 253.2 | 239.4 | 225.5 | 211.7 | 197.8 |
| 67.0 | 244.4 | 231.7 | 219.0 | 206.3 | 193.5 | 180.8 |
| 66.0 | 221.8 | 210.2 | 198.6 | 187.0 | 175.4 | 163.8 |
| 65.0 | 199.1 | 188.6 | 178.2 | 167.7 | 157.3 | 146.8 |

^{*}Base case: 0% (row); 68sen (column)



Sensitivity of TP to sales volume and ASP

| Sales Volume Growth (row) EBIT ASP/stick (column) | 0% | -5% | -10% | -15% | -20% | -25% |
|--|-------|-------|-------|-------|-------|-------|
| 70.0 | 13.57 | 13.32 | 13.07 | 12.83 | 12.58 | 12.33 |
| 69.0 | 12.74 | 12.53 | 12.33 | 12.12 | 11.92 | 11.71 |
| 68.0 | 11.90 | 11.75 | 11.58 | 11.42 | 11.25 | 11.09 |
| 67.0 | 11.08 | 10.96 | 10.84 | 10.71 | 10.59 | 10.47 |
| 66.0 | 10.25 | 10.17 | 10.09 | 10.01 | 9.93 | 9.85 |
| 65.0 | 9.43 | 9.39 | 9.35 | 9.31 | 9.27 | 9.23 |

Source: AllianceDBS, Bloomberg Finance L.P

Sensitivity of FY20 dividend yield to sales volume and ASP

| Sales Volume Growth (row) EBIT ASP/stick (column) | 0% | -5% | -10% | -15% | -20% | -25% |
|--|-------|------|------|------|------|------|
| 70.0 | 10.1% | 9.6% | 9.1% | 8.6% | 8.0% | 7.5% |
| 69.0 | 9.4% | 8.9% | 8.4% | 7.9% | 7.5% | 7.0% |
| 68.0 | 8.7% | 8.2% | 7.8% | 7.3% | 6.9% | 6.4% |
| 67.0 | 7.9% | 7.5% | 7.1% | 6.7% | 6.3% | 5.9% |
| 66.0 | 7.2% | 6.8% | 6.4% | 6.1% | 5.7% | 5.3% |
| 65.0 | 6.5% | 6.1% | 5.8% | 5.4% | 5.1% | 4.8% |

Source: AllianceDBS, Bloomberg Finance L.P



CRITICAL DATA POINTS TO WATCH


Pricing policy drives earnings. Operating in an oligopoly with three leading players (ROTH, Japan Tobacco International and Philip Morris International) in the legal cigarette market, the ability of ROTH to raise prices to pass on increased costs (mainly arising from hikes in the country's sin taxes) without affecting its market share and profit remains its key earnings driver.


Influence on market price. ROTH has a commanding market share of c.54% in the legal cigarette market in Malaysia. Such a dominant position has, to some extent, allowed the group to be a price-leader.

Optimising costs. To mitigate the impact of illicit trade on its earnings, the group has undertaken cost cutting initiatives such as overhead savings, lower marketing investment and distribution cost. As a result, its operating expenses in FY19 fell by 18% compared to the same period the previous year (FY18: -4%).

High illicit trade and alternatives. Given ROTH's dominant position in the legal cigarette market, high illicit trade continues to be a drag on its earnings growth. Despite strong enforcement recently by the authorities, illicit trade remains high at 68% of the estimated total market share. The increasing popularity of alternatives such as tobacco heating products (THP) could pose new challenges to the industry.

New government measures. The Malaysian tobacco industry's landscape remains challenging due to, (1) declining cigarette consumption per capita due to an increasingly health conscious population, (2) continuously high illicit trade, (3) regulatory risks and, (4) emergence of alternative offerings such as THP.










Source: Company, AllianceDBS



Graph 1: ROTH's share price movement relative to FBM KLCI index movement (m-o-m)



Source: Company, Bloomberg Finance L.P., AllianceDBS

ROTH's share price vs sales volume


BAT Volume (bn) Illegal volume (bn) bn RM 70.00 3.50 60.00 3.00 50.00 2.50 40.00 2.00 30.00 1.50 20.00 1.00 0.50 10.00 2Q16 4Q19 4Q15 1Q16 3016 4Q16 1017 2017 3018 4Q18 1015 3017 4017 1018 2018

Remarks

As the largest distributor of cigarettes in Malaysia with c.54% market share of the legal cigarette market, ROTH's share price performance correlates strongly with the expansion and contraction of the group's domestic sales volume (correlation coefficient of 0.9), given that the group mainly derives its earnings from domestic consumption.

Source: Company, Bloomberg Finance L.P., AllianceDBS

ROTH's share price vs dividend per share (ex-special div)



Source: Company, Bloomberg Finance L.P., AllianceDBS

Remarks

With strong cash flow generating operations and consistently high dividend payout, ROTH is viewed as a dividend yield stock by the investment community. As such, the group's share price performance is closely correlated with its ability to pay out higher dividends (correlation coefficient of 0.8).



Balance Sheet:

Healthy balance sheet. The group's balance sheet remains healthy despite its net gearing position of about 0.8x (mainly used for working capital), given the strong cash generation of its business, which allows the group to comfortably meet its debt obligations and maintain a high dividend payout without overstretching its balance sheet.

Share Price Drivers:

Decline in illicit trade. A consistent drop in market share of illegal cigarettes could be a major game changer as it is an early indicator of the industry's performance.


Key Risks:


High illicit trade. Counterfeit and smuggled cigarettes could continue to cap domestic sales volume in the legal cigarette market. Illicit trade rose from 47.1% in November 2015 to 58% of total market share in December 2016. Combined with vapour products, illegal cigarettes' market share hit an all-time high of 74% in September 2019. As of December 2019, illegal market share stood at 68%


High taxes. In view of the persistently high illicit trade and low consumer affordability, we are doubtful of the ability of tobacco players to fully pass on any potential sales tax hike.


Company Background


ROTH is a major distributor of cigarettes in Malaysia. Its portfolio includes the Dunhill, Pall Mall and Kent brands. The group has a c.54% market share of legal cigarettes in Malaysia. It used to manufacture cigarettes in Malaysia to cater to local and overseas demand but ceased the manufacturing operations in 2017. It is now sources its products from other British American Tobacco Group's factories in the region such as Indonesia and Singapore. ROTH announced a special dividend of 46sen following the disposal of its land that used to house its manufacturing facility.













| Key Assumptions | | | | | |
|--|--------------|--------------|--------------|--------------|--------------|
| FY Dec | 2018A | 2019A | 2020F | 2021F | 2022F |
| Domestic Legitimate trade volume (bn sticks) | 7.37 | 6.61 | 6.64 | 6.68 | 6.71 |
| Illicit trade market share Gross margin (%) | 63.0 31.7 | 68.0 28.6 | 68.0 22.7 | 68.0 23.7 | 68.0 23.7 |

Drop due to lower ASP and volume

Income Statement (RMm)

| FY Dec | 2018A | 2019A | 2020F | 2021F | 2022F |
|-----------------------------|---------|---------|---------|---------|---------|
| Revenue | 2,823 | 2,509 | 2,439 | 2,488 | 2,500 |
| Cost of Goods Sold | (1,928) | (1,791) | (1,885) | (1,899) | (1,909) |
| Gross Profit | 895 | 718 | 554 | 588 | 591 |
| Other Opng (Exp)/Inc | (279) | (218) | (180) _ | (181) | (179) |
| Operating Profit | 617 | 500 | 374 | 407 | 412 |
| Other Non Opg (Exp)/Inc | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Associates & JV Inc | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Interest (Exp)/Inc | (12.2) | (14.7) | (15.2) | (14.6) | (14.4) |
| Exceptional Gain/(Loss) | 20.0 | (21.3) | 0.0 | 0.0 | 0.0 |
| Pre-tax Profit | 624 | 464 | 359 | 393 | 398 |
| Tax | (154) | (117) | (90.5) | (99.1) | (100) |
| Minority Interest | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Preference Dividend | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | 469 | 346 | 268 | 294 | 298 |
| Net Profit before Except. | 449 | 367 | 268 | 294 | 298 |
| EBITDA | 624 | 514 | 392 | 429 | 437 |
| Growth | | | | | |
| Revenue Gth (%) | (6.0) | (11.1) | (2.8) | 2.0 | 0.5 |
| EBITDA Gth (%) | (10.0) | (17.6) | (23.7) | 9.4 | 2.0 |
| Opg Profit Gth (%) | (9.4) | (19.0) | (25.1) | 8.9 | 1.2 |
| Net Profit Gth (Pre-ex) (%) | (14.1) | (18.2) | (26.8) | 9.4 | 1.3 |
| Margins & Ratio | | | | | |
| Gross Margins (%) | 31.7 | 28.6 | 22.7 | 23.6 | 23.6 |
| Opg Profit Margin (%) | 21.8 | 19.9 | 15.3 | 16.4 | 16.5 |
| Net Profit Margin (%) | 16.6 | 13.8 | 11.0 | 11.8 | 11.9 |
| ROAE (%) | 116.6 | 85.3 | 69.7 | 73.6 | 68.9 |
| ROA (%) | 43.7 | 32.5 | 26.3 | 28.5 | 28.1 |
| ROCE (%) | 58.3 | 44.9 | 33.9 | 36.7 | 35.9 |
| Div Payout Ratio (%) | 94.5 | 97.5 | 90.0 | 90.0 | 90.0 |
| Net Interest Cover (x) | 50.4 | 34.0 | 24.7 | 27.9 | 28.6 |

Lower opex following restructuring exercise in 2019

Source: Company, AllianceDBS



| Quarterly / Interim Income | | | 202212 | 202212 | 400040 | | |
|-----------------------------|--------|--------|--------|--------|------------------|---|--------------------------------|
| FY Dec | 4Q2018 | 1Q2019 | 2Q2019 | 3Q2019 | 4Q2019 | | |
| Revenue | 771 | 621 | 641 | 584 | 662 | | |
| Cost of Goods Sold | (547) | (440) | (457) | (423) | (471) | | |
| Gross Profit | 223 | 181 | 184 | 162 | 192 | | |
| Other Oper. (Exp)/Inc | (70.1) | (60.3) | (77.0) | (49.1) | (31.9) | | |
| Operating Profit | 153 | 120 | 107 | 112 | 160 | | |
| Other Non Opg (Exp)/Inc | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | |
| Associates & JV Inc | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | |
| Net Interest (Exp)/Inc | (3.1) | (3.1) | (4.1) | (3.6) | (4.0) | | |
| xceptional Gain/(Loss) | 8.94 | (8.0) | 0.26 | 0.0 | (21.8) | | |
| Pre-tax Profit | 159 | 117 | 103 | 109 | 134 | | |
| ax | (42.6) | (28.0) | (26.4) | (25.7) | (36.4) | | |
| Minority Interest | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | |
| Net Profit | 116 | 88.6 | 76.3 | 83.1 | 97.7 | | |
| Net profit bef Except. | 107 | 89.4 | 76.0 | 83.1 | 119 | | |
| BITDA | 155 | 124 | 110 | 116 | 164 | | |
| Growth | | | | | | | |
| Revenue Gth (%) | 4.8 | (19.4) | 3.2 | (8.8) | 13.4 | | |
| BITDA Gth (%) | (15.3) | (20.0) | (11.2) | 5.2 | 41.1 | | |
| Opg Profit Gth (%) | (15.5) | (21.4) | (11.5) | 5.5 | 42.3 | | |
| Net Profit Gth (Pre-ex) (%) | (20.6) | (16.8) | (15.0) | 9.4 | 43.7 | | |
| Vlargins | | | | | | | |
| Gross Margins (%) | 29.0 | 29.1 | 28.6 | 27.6 | 29.0 | | |
| Opg Profit Margins (%) | 19.9 | 19.4 | 16.6 | 19.2 | 24.1 | | Margin improved |
| let Profit Margins (%) | 15.1 | 14.3 | 11.9 | 14.2 | 14.7 | | restructuring cost – thanks to |
| Balance Sheet (RMm) | | | | | | | better sales mix |
| Y Dec | 2018A | 2019A | 2020F | 2021F | 2022F | | |
| | | | 60.3 | | <u>.</u> | | |
| Net Fixed Assets | 44.0 | 65.5 | 69.3 | 69.6 | 66.5 | | |
| nvts in Associates & JVs | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | |
| Other LT Assets | 444 | 432 | 434 | 435 | 437 | | |
| Cash & ST Invts | 79.5 | 20.8 | 8.17 | 35.9 | 57.2 | | |
| nventory | 162 | 98.3 | 95.5 | 97.4 | 97.9 | | |
| Debtors | 361 | 403 | 397 | 401 | 402 | | |
| Other Current Assets | 9.42 | 8.22 | 8.22 | 8.22 | 8.22 | | |
| otal Assets | 1,101 | 1,028 | 1,012 | 1,048 | 1,069 | | |
| T Debt | 410 | 425 | 410 | 410 | 400 | | |
| Creditor | 236 | 171 | 177 | 177 | 178 | | |
| Other Current Liab | 33.6 | 21.7 | 21.7 | 21.7 | 21.7 | | |
| .T Debt | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | |
| Other LT Liabilities | 0.0 | 21.8 | 21.8 | 21.8 | 21.8 | | |
| Shareholder's Equity | 422 | 389 | 382 | 417 | 447 | | |
| Minority Interests | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | |
| Fotal Cap. & Liab. | 1,101 | 1,028 | 1,012 | 1,048 | 1,069 | | |
| Non-Cash Wkg. Capital | 264 | 317 | 302 | 308 | 309 | | |
| let Cash/(Debt) | (330) | (405) | (402) | (374) | (343) | | |
| Debtors Turn (avg days) | 43.0 | 55.6 | 59.8 | 58.5 | 58.6 | | |
| Creditors Turn (avg days) | 48.7 | 41.8 | 33.9 | 34.4 | 34.4 | | |
| nventory Turn (avg days) | 37.9 | 26.8 | 18.9 | 18.7 | 18.9 | | |
| Asset Turnover (x) | 2.6 | 2.4 | 2.4 | 2.4 | 2.4 | | |
| Current Ratio (x) | 0.9 | 0.9 | 0.8 | 0.9 | 0.9 | Г | |
| Quick Ratio (x) | 0.6 | 0.7 | 0.7 | 0.7 | 0.8 | | Mainly due to working |
| let Debt/Equity (X) | 0.8 | 1.0 | 1.1 | 0.9 | _ 0.8 | | capital |
| Net Debt/Equity (X) | 0.8 | 1.0 | 1.1 | 0.9 | 0.8 | L | |
| TO LOU LYUILY CA IVII (A) | 0.0 | 1.0 | 1.1 | 0.5 - | 0.0 | | |
| Capex to Debt (%) | 4.2 | 1.0 | 5.6 | 5.6 | 5.7 | | |


Source: Company, AllianceDBS



| Cash Flow Statement (RM | - | | | | |
|-------------------------|--------|--------|--------|--------|--------|
| FY Dec | 2018A | 2019A | 2020F | 2021F | 2022F |
| Pre-Tax Profit | 623 | 462 | 359 | 393 | 398 |
| Dep. & Amort. | 7.05 | 14.2 | 17.7 | 21.1 | 24.6 |
| Tax Paid | (124) | (117) | (90.5) | (99.1) | (100) |
| Assoc. & JV Inc/(loss) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Chg in Wkg.Cap. | (24.3) | (42.6) | 15.0 | (5.5) | (1.1) |
| Other Operating CF | 11.5 | 14.0 | 15.2 | 14.6 | 14.4 |
| Net Operating CF | 494 | 331 | 316 | 324 | 336 |
| Capital Exp.(net) | (17.2) | (4.2) | (22.9) | (22.9) | (22.9) |
| Other Invts.(net) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Invts in Assoc. & JV | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Div from Assoc & JV | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other Investing CF | 3.29 | 2.45 | 0.79 | 1.04 | 1.04 |
| Net Investing CF | (14.0) | (1.7) | (22.1) | (21.9) | (21.9) |
| Div Paid | (431) | (377) | (275) | (259) | (267) |
| Chg in Gross Debt | 32.0 | 11.0 | (15.4) | 0.0 | (10.0) |
| Capital Issues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other Financing CF | (13.5) | (21.8) | (16.0) | (15.7) | (15.5) |
| Net Financing CF | (413) | (388) | (307) | (274) | (293) |
| Currency Adjustments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Chg in Cash | 67.1 | (58.2) | (12.6) | 27.8 | 21.3 |
| Opg CFPS (sen) | 181 | 131 | 106 | 115 | 118 |
| Free CFPS (sen) | 167 | 115 | 103 | 105 | 110 |
| | | | | | |

Source: Company, AllianceDBS

Target Price & Ratings History



Note: Share price and Target price are adjusted for corporate actions.

Source: AllianceDBS

Analyst: Abdul Azim Muhthar

| S.No. | Date of Report | Closing Price | 12-mth Target Price | Rating |
|-------|-------------------|------------------|---------------------------|--------------|
| 1: | 29 May 19 | 31.00 | 30.00 | HOLD |
| 2: | 26 Jul 19 | 26.20 | 25.00 | FULLY VALUED |
| 3: | 01 Nov 19 | 18.50 | 16.30 | FULLY VALUED |
| 4: | 21 Feb 20 | 14.34 | 17.10 | BUY |



AllianceDBS recommendations are based on an Absolute Total Return* Rating system, defined as follows:

STRONG BUY (>20% total return over the next 3 months, with identifiable share price catalysts within this time frame)

BUY (>15% total return over the next 12 months for small caps, >10% for large caps)

HOLD (-10% to +15% total return over the next 12 months for small caps, -10% to +10% for large caps)

FULLY VALUED (negative total return, i.e., > -10% over the next 12 months)

SELL (negative total return of > -20% over the next 3 months, with identifiable share price catalysts within this time frame)

*Share price appreciation + dividends

Completed Date: 24 Mar 2020 19:52:40 (MYT) Dissemination Date: 25 Mar 2020 07:27:11 (MYT)

Sources for all charts and tables are AllianceDBS unless otherwise specified.

GENERAL DISCLOSURE/DISCLAIMER

This report is prepared by AllianceDBS Research Sdn Bhd ("AllianceDBS"). This report is solely intended for the clients of DBS Bank Ltd, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of AllianceDBS Research Sdn Bhd ("AllianceDBS").

The research set out in this report is based on information obtained from sources believed to be reliable, but we (which collectively refers to DBS Bank Ltd, its respective connected and associated corporations, affiliates and their respective directors, officers, employees and agents (collectively, the "DBS Group") have not conducted due diligence on any of the companies, verified any information or sources or taken into account any other factors which we may consider to be relevant or appropriate in preparing the research. Accordingly, we do not make any representation or warranty as to the accuracy, completeness or correctness of the research set out in this report. Opinions expressed are subject to change without notice. This research is prepared for general circulation. Any recommendation contained in this document does not have regard to the specific investment objectives, financial situation and the particular needs of any specific addressee. This document is for the information of addressees only and is not to be taken in substitution for the exercise of judgement by addressees, who should obtain separate independent legal or financial advice. The DBS Group accepts no liability whatsoever for any direct, indirect and/or consequential loss (including any claims for loss of profit) arising from any use of and/or reliance upon this document and/or further communication given in relation to this document. This document is not to be construed as an offer or a solicitation of an offer to buy or sell any securities. The DBS Group, along with its affiliates and/or persons associated with any of them may from time to time have interests in the securities mentioned in this document. The DBS Group, may have positions in, and may effect transactions in securities mentioned herein and may also perform or seek to perform broking, investment banking and other banking services for these companies.

Any valuations, opinions, estimates, forecasts, ratings or risk assessments herein constitutes a judgment as of the date of this report, and there can be no assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments. The information in this document is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed, it may not contain all material information concerning the company (or companies) referred to in this report and the DBS Group is under no obligation to update the information in this report.

This publication has not been reviewed or authorized by any regulatory authority in Singapore, Hong Kong or elsewhere. There is no planned schedule or frequency for updating research publication relating to any issuer.

The valuations, opinions, estimates, forecasts, ratings or risk assessments described in this report were based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. It can be expected that one or more of the estimates on which the valuations, opinions, estimates, forecasts, ratings or risk assessments were based will not materialize or will vary significantly from actual results. Therefore, the inclusion of the valuations, opinions, estimates, forecasts, ratings or risk assessments described herein IS NOT TO BE RELIED UPON as a representation and/or warranty by the DBS Group (and/or any persons associated with the aforesaid entities), that:

- (a) such valuations, opinions, estimates, forecasts, ratings or risk assessments or their underlying assumptions will be achieved, and
- (b) there is any assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments stated therein.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.



Any assumptions made in this report that refers to commodities, are for the purposes of making forecasts for the company (or companies) mentioned herein. They are not to be construed as recommendations to trade in the physical commodity or in the futures contract relating to the commodity referred to in this report.

DBSVUSA, a US-registered broker-dealer, does not have its own investment banking or research department, has not participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months and does not engage in market-making.

ANALYST CERTIFICATION

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible for the content of this research report, in part or in whole, certifies that he or his associate does not serve as an officer of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant) and the research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests in relation to an issuer or a new listing applicant that the analyst reviews. DBS Group has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the DBS Group and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of DBS Group's compensation to any specific investment banking function of the DBS Group.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES

- 1. DBS Bank Ltd, DBS HK, DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS") or their subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of 28 Feb 2020.
- 2. Neither DBS Bank Ltd nor DBS HK market makes in equity securities of the issuer(s) or company(ies) mentioned in this Research Report.

Compensation for investment banking services:

3. DBSVUSA does not have its own investment banking or research department, nor has it participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months. Any US persons wishing to obtain further information, including any clarification on disclosures in this disclaimer, or to effect a transaction in any security discussed in this document should contact DBSVUSA exclusively.

Disclosure of previous investment recommendation produced:

4. DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS"), their subsidiaries and/or other affiliates may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by DBS Bank Ltd, DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS"), their subsidiaries and/or other affiliates in the preceding 12 months.

An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial interest is defined as interests that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.



| RESTRICTIONS (| ON DISTRIBUTION |
|----------------|--|
| General | This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. |
| Australia | This report is being distributed in Australia by DBS Bank Ltd, DBSVS or DBSV HK. DBS Bank Ltd holds Australian Financial Services Licence no. 475946. DBSVS and DBSV HK are exempted from the requirement to hold an Australian Financial Services Licence under the Corporation Act 2001 ("CA") in respect of financial services provided to the recipients. Both DBS Bank Ltd and DBSVS are regulated by the Monetary Authority of Singapore under the laws of Singapore, and DBSV HK is regulated by the Hong Kong Securities and Futures Commission under the laws of Hong Kong, which differ from Australian laws. Distribution of this report is intended only for "wholesale investors" within the meaning of the CA. |
| Hong Kong | This report has been prepared by an entity(ies) which is not licensed by the Hong Kong Securities and Futures Commission to carry on the regulated activity of advising on securities pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). This report is being distributed in Hong Kong and is attributable to DBS Bank (Hong Kong) Limited, a registered institution registered with the Hong Kong Securities and Futures Commission to carry on the regulated activity of advising on securities pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). DBS Bank Ltd., Hong Kong Branch is a limited liability company incorporated in Singapore. For any query regarding the materials herein, please contact Carol Wu (Reg No. AH8283) at dbsvhk@dbs.com |
| Indonesia | This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia. |
| Malaysia | This report is distributed in Malaysia by AllianceDBS Research Sdn Bhd ("ADBSR"). Recipients of this report, received from ADBSR are to contact the undersigned at 603-2604 3333 in respect of any matters arising from or in connection with this report. In addition to the General Disclosure/Disclaimer found at the preceding page, recipients of this report are advised that ADBSR (the preparer of this report), its holding company Alliance Investment Bank Berhad, their respective connected and associated corporations, affiliates, their directors, officers, employees, agents and parties related or associated with any of them may have positions in, and may effect transactions in the securities mentioned herein and may also perform or seek to perform broking, investment banking/corporate advisory and other services for the subject companies. They may also have received compensation and/or seek to obtain compensation for broking, investment banking/corporate advisory and other services from the subject companies. |
| | Wong Ming Tek, Executive Director, ADBSR |
| Singapore | This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 196800306E) or DBSVS (Company Regn No. 198600294G), both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, DBS Bank Ltd accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report. |



| Thailand | This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd. |
|---|--|
| United Kingdom | This report is produced by AllianceDBS Research Sdn Bhd which is regulated by the Securities Commission Malaysia. This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and |
| | associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication. |
| Dubai International Financial Centre | This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at units 608 - 610, 6 th Floor, Gate Precinct Building 5, PO Box 506538, DIFC, Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it. |
| United Arab Emirates | This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent. |
| United States | This report was prepared by AllianceDBS Research Sdn Bhd ("AllianceDBS"). DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate. |
| Other jurisdictions | In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. |



DBS Regional Research Offices

HONG KONG DBS (Hong Kong) Ltd

Contact: Carol Wu 13th Floor One Island East, 18 Westlands Road, Quarry Bay, Hong Kong Tel: 852 3668 4181 Fax: 852 2521 1812

e-mail: dbsvhk@dbs.com

THAILAND DBS Vickers Securities (Thailand) Co Ltd

Contact: Chanpen Sirithanarattanakul 989 Siam Piwat Tower Building, 9th, 14th-15th Floor Rama 1 Road, Pathumwan, Bangkok Thailand 10330 Tel. 66 2 857 7831 Fax: 66 2 658 1269

e-mail: research@th.dbs.com Company Regn. No 0105539127012 Securities and Exchange Commission, Thailand

MALAYSIA

AllianceDBS Research Sdn Bhd Contact: Wong Ming Tek (128540 U)

19th Floor, Menara Multi-Purpose, Capital Square, 8 Jalan Munshi Abdullah 50100 Kuala Lumpur, Malaysia. Tel.: 603 2604 3333 Fax: 603 2604 3921

e-mail: general@alliancedbs.com

INDONESIA PT DBS Vickers Sekuritas (Indonesia)

Contact: Maynard Priajaya Arif DBS Bank Tower Ciputra World 1, 32/F Jl. Prof. Dr. Satrio Kav. 3-5 Jakarta 12940, Indonesia Tel: 62 21 3003 4900 Fax: 6221 3003 4943

e-mail: indonesiaresearch@dbs.com

SINGAPORE **DBS Bank Ltd**

Contact: Janice Chua 12 Marina Boulevard, Marina Bay Financial Centre Tower 3 Singapore 018982 Tel: 65 6878 8888 Fax: 65 65353 418

e-mail: equityresearch@dbs.com Company Regn. No. 196800306E